What is 3DBio Therapeutics?
3DBio Therapeutics operates at the intersection of biotechnology and advanced manufacturing, specializing in the creation of living tissue implants. The company's core value proposition lies in its ability to design and manufacture patient-specific tissues, effectively addressing the limitations of traditional organ and tissue replacement therapies. Through its integrated platform, which includes the GMPrint 3D-bioprinter and ColVivo bio-ink, the firm provides a comprehensive solution for regenerative medicine. By focusing on proprietary cell processes that meet stringent FDA requirements, 3DBio Therapeutics is establishing a new paradigm in personalized medicine, moving beyond theoretical research into functional, therapeutic tissue generation.
How much funding has 3DBio Therapeutics raised?
3DBio Therapeutics has raised a total of $20M across 1 funding round:
Other Financing Round
$20M
Other Financing Round (2020): $20M with participation from Western Technology Investment, BlueSeed Ventures, Barer & Son Capital, and Alexandria Venture Investments
Key Investors in 3DBio Therapeutics
Western Technology Investment
Western Technology Investment (WTI) specializes in providing venture debt to assist startups in financing their growth while minimizing shareholder dilution. The firm offers scalable credit facilities suitable for businesses from their seed stage to public listing.
Alexandria Venture Investments
Alexandria Real Estate Equities, Inc. is a real estate investment trust that engages in the development and management of properties specifically for the life sciences industry, supporting biotechnology and medical device entities.
BlueSeed Ventures
Undisclosed investor participating in the funding round.
What's next for 3DBio Therapeutics?
With the recent capital deployment, 3DBio Therapeutics is expected to accelerate its clinical development pipeline and refine its manufacturing infrastructure. The strategic focus will likely center on optimizing the scalability of its bioprinting processes to support larger patient cohorts and diverse therapeutic indications. As the company matures, the integration of its technology into standard clinical workflows will be paramount. Investors are closely monitoring the firm's ability to navigate regulatory hurdles and demonstrate long-term efficacy in human trials, which will be the primary catalyst for future valuation growth and potential market leadership in the bioprinting industry.
See full 3DBio Therapeutics company page
